Xenon Pharmaceuticals Statistics
Total Valuation
XENE has a market cap or net worth of $5.22 billion. The enterprise value is $4.64 billion.
Important Dates
The last earnings date was Thursday, February 26, 2026, after market close.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XENE has 83.19 million shares outstanding. The number of shares has increased by 1.75% in one year.
| Current Share Class | 83.19M |
| Shares Outstanding | 83.19M |
| Shares Change (YoY) | +1.75% |
| Shares Change (QoQ) | +1.11% |
| Owned by Insiders (%) | 0.10% |
| Owned by Institutions (%) | 96.10% |
| Float | 77.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 696.14 |
| Forward PS | n/a |
| PB Ratio | 8.63 |
| P/TBV Ratio | 8.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 619.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.42, with a Debt / Equity ratio of 0.01.
| Current Ratio | 13.42 |
| Quick Ratio | 13.17 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -51.76% and return on invested capital (ROIC) is -34.45%.
| Return on Equity (ROE) | -51.76% |
| Return on Assets (ROA) | -32.58% |
| Return on Invested Capital (ROIC) | -34.45% |
| Return on Capital Employed (ROCE) | -63.09% |
| Weighted Average Cost of Capital (WACC) | 9.43% |
| Revenue Per Employee | $20,270 |
| Profits Per Employee | -$934,892 |
| Employee Count | 370 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, XENE has paid $1.02 million in taxes.
| Income Tax | 1.02M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +71.95% in the last 52 weeks. The beta is 0.94, so XENE's price volatility has been similar to the market average.
| Beta (5Y) | 0.94 |
| 52-Week Price Change | +71.95% |
| 50-Day Moving Average | 42.78 |
| 200-Day Moving Average | 38.49 |
| Relative Strength Index (RSI) | 82.90 |
| Average Volume (20 Days) | 1,463,632 |
Short Selling Information
The latest short interest is 5.38 million, so 6.47% of the outstanding shares have been sold short.
| Short Interest | 5.38M |
| Short Previous Month | 5.54M |
| Short % of Shares Out | 6.47% |
| Short % of Float | 6.93% |
| Short Ratio (days to cover) | 6.61 |
Income Statement
In the last 12 months, XENE had revenue of $7.50 million and -$345.91 million in losses. Loss per share was -$4.36.
| Revenue | 7.50M |
| Gross Profit | -293.44M |
| Operating Income | -373.07M |
| Pretax Income | -344.89M |
| Net Income | -345.91M |
| EBITDA | -370.53M |
| EBIT | -373.07M |
| Loss Per Share | -$4.36 |
Full Income StatementBalance Sheet
The company has $548.89 million in cash and $7.94 million in debt, with a net cash position of $578.09 million or $6.95 per share.
| Cash & Cash Equivalents | 548.89M |
| Total Debt | 7.94M |
| Net Cash | 578.09M |
| Net Cash Per Share | $6.95 |
| Equity (Book Value) | 581.76M |
| Book Value Per Share | 7.27 |
| Working Capital | 518.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$279.12 million and capital expenditures -$799,000, giving a free cash flow of -$279.92 million.
| Operating Cash Flow | -279.12M |
| Capital Expenditures | -799,000 |
| Free Cash Flow | -279.92M |
| FCF Per Share | -$3.36 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -4,974.27% |
| Pretax Margin | -4,598.59% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XENE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.75% |
| Shareholder Yield | n/a |
| Earnings Yield | -6.63% |
| FCF Yield | -5.36% |
Analyst Forecast
The average price target for XENE is $63.92, which is 1.85% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $63.92 |
| Price Target Difference | 1.85% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 169.13% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XENE has an Altman Z-Score of 29.45 and a Piotroski F-Score of 1.
| Altman Z-Score | 29.45 |
| Piotroski F-Score | 1 |
